EE201300005A - Ravimkoostis - Google Patents

Ravimkoostis

Info

Publication number
EE201300005A
EE201300005A EEP201300005A EEP201300005A EE201300005A EE 201300005 A EE201300005 A EE 201300005A EE P201300005 A EEP201300005 A EE P201300005A EE P201300005 A EEP201300005 A EE P201300005A EE 201300005 A EE201300005 A EE 201300005A
Authority
EE
Estonia
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
EEP201300005A
Other languages
English (en)
Inventor
Iliich Epshtein Oleg
Alexandrovna Sergeeva Svetlana
Fyodorovna Dolgovyh Liudmila
Anatolievna Kheyfets Irina
Leonidovna Dugina Julia
Alexandrovna Zabolotneva Julia
Alexandrovich Tarasov Sergey
Original Assignee
Iliich Epshtein Oleg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE201300005(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010129289/15A external-priority patent/RU2552221C2/ru
Priority claimed from RU2010130350/15A external-priority patent/RU2533224C2/ru
Priority claimed from RU2011122407A external-priority patent/RU2610438C2/ru
Application filed by Iliich Epshtein Oleg filed Critical Iliich Epshtein Oleg
Publication of EE201300005A publication Critical patent/EE201300005A/et
Publication of EE05760B1 publication Critical patent/EE05760B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP201300005A 2010-07-15 2011-07-15 Ravimkoostis EE05760B1 (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
RU2010129289/15A RU2552221C2 (ru) 2010-07-15 2010-07-15 Способ лечения ожирения и сопутствующих метаболических расстройств и лекарственное средство для лечения ожирения и сопутствующих метаболических расстройств
RU2010130350/15A RU2533224C2 (ru) 2010-07-21 2010-07-21 Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
RU2011122407A RU2610438C2 (ru) 2011-06-02 2011-06-02 Способ лечения патологического синдрома и лекарственное средство центрального и периферического действия для лечения патологического синдрома
PCT/IB2011/002404 WO2012007847A2 (en) 2010-07-15 2011-07-15 Pharmaceutical compositions and methods of treatment

Publications (2)

Publication Number Publication Date
EE201300005A true EE201300005A (et) 2013-08-15
EE05760B1 EE05760B1 (et) 2016-03-15

Family

ID=44899164

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP201300005A EE05760B1 (et) 2010-07-15 2011-07-15 Ravimkoostis

Country Status (30)

Country Link
US (1) US8865163B2 (et)
EP (1) EP2593477A2 (et)
JP (1) JP2013535436A (et)
KR (1) KR20140012009A (et)
CN (1) CN103124742A (et)
AR (1) AR082246A1 (et)
AU (1) AU2011278040B2 (et)
BR (1) BR112013000841A2 (et)
CA (1) CA2805091A1 (et)
CL (1) CL2013000098A1 (et)
CZ (1) CZ2013104A3 (et)
DE (1) DE112011102349T5 (et)
DK (1) DK201370078A (et)
EA (1) EA029400B1 (et)
EE (1) EE05760B1 (et)
ES (1) ES2542042R1 (et)
FI (1) FI20135146A7 (et)
FR (1) FR2962653A1 (et)
GB (1) GB2496076B (et)
IT (1) ITTO20110641A1 (et)
LT (1) LT5987B (et)
MX (1) MX361778B (et)
MY (1) MY158183A (et)
NO (1) NO20130219A1 (et)
NZ (1) NZ606768A (et)
PE (1) PE20131338A1 (et)
PH (1) PH12013500109A1 (et)
SE (1) SE1350179A1 (et)
SG (1) SG187037A1 (et)
WO (1) WO2012007847A2 (et)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2012007849A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating genitourinary system disorders
NZ606767A (en) 2010-07-15 2015-08-28 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
CA2804967A1 (en) 2010-07-15 2012-02-09 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
FR2962910A1 (fr) * 2010-07-21 2012-01-27 Oleg Iliich Epshtein Compositions pharmaceutiques d'association et leur utilisation dans un procede du traitement du vertige, de la kinetose et de la dystonie vasculaire vegetative
MY160979A (en) * 2010-07-21 2017-03-31 Oleg Llich Epshtein A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
PE20130387A1 (es) * 2010-07-21 2013-03-30 Oleg Iliich Epshtein Composicion farmaceutica y combinacion y metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria
US8987206B2 (en) 2010-07-21 2015-03-24 Oleg Iliich Epshtein Method of treating attention deficit hyperactivity disorder
ES2510940R1 (es) * 2010-08-06 2015-03-27 Oleg Iliich Epshtein Composición farmacéutica combinada y su uso para preparar un medicamento destinado al tratamiento y prevención de las enfermedades infecciosas
RU2013111961A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) * 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
PE20170258A1 (es) * 2014-03-27 2017-03-23 Bird Rock Bio Inc Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
CN104524568B (zh) * 2015-01-08 2018-04-20 中国人民解放军第二军医大学 一种治疗肥胖症的药物组合物及其应用
AU2016330471B2 (en) * 2015-09-30 2022-09-29 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (CB1) receptor
JP2022545178A (ja) * 2019-08-29 2022-10-26 イリイチ・エプシテイン オレグ 感染症を治療するための医薬及び方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
AU723812B2 (en) 1996-02-12 2000-09-07 Oleg Iliich Epshtein Medicinal preparation and a method of medicinal action on human organism
US5849528A (en) 1997-08-21 1998-12-15 Incyte Pharmaceuticals, Inc.. Polynucleotides encoding a human S100 protein
RU2156621C1 (ru) 1999-03-04 2000-09-27 Эпштейн Олег Ильич Нейротропное лекарственное средство
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2201255C1 (ru) 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
RU2209084C1 (ru) * 2001-12-26 2003-07-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения депрессивных расстройств
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76640C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
UA76639C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
CN101107003B (zh) 2003-03-14 2012-08-08 营养学研究有限公司 用于治疗疼痛和/或炎症的顺势疗法的配剂
US20050100513A1 (en) * 2003-11-10 2005-05-12 Watkins Mary B. Homeopathic method and system for treating nicotine addiction
EP1574211A1 (en) * 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
MX2008015621A (es) 2006-06-06 2009-03-06 Oleg Iliich Epshtein Agente medicinal para el tratamiento de obesidad, diabetes y enfermedades relacionadas con la tolerancia deteriorada de glucosa.
RU2437678C2 (ru) 2006-06-06 2011-12-27 Олег Ильич Эпштейн Лекарственное средство для перорального лечения ожирения и способ получения твердой лекарственной формы для пероральной терапии ожирения
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
PE20080926A1 (es) * 2006-10-23 2008-07-19 Lilly Co Eli Compuestos cb1
EP1985295A1 (en) * 2007-04-04 2008-10-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Selective inhibitors of CB2 receptor expression and/or activity for the treatment of obesity and obesity-related disorders
JP2010132631A (ja) * 2008-11-04 2010-06-17 Bizen Chemical Co Ltd カンナビノイド受容体のインバースアゴニストおよびアンタゴニスト活性を有する組成物
CA2804967A1 (en) 2010-07-15 2012-02-09 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
EP2593138A2 (en) 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
MY160979A (en) 2010-07-21 2017-03-31 Oleg Llich Epshtein A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders
FR2962910A1 (fr) 2010-07-21 2012-01-27 Oleg Iliich Epshtein Compositions pharmaceutiques d'association et leur utilisation dans un procede du traitement du vertige, de la kinetose et de la dystonie vasculaire vegetative
WO2012014078A2 (en) 2010-07-21 2012-02-02 Olge Iliich Epshtein Method of treatment of organic diseases of nervous system, psychoorganic syndrome and encephalopathy
US20130058982A1 (en) 2010-07-21 2013-03-07 Oleg Iliich Epshtein Method of treating Alzheimer's disease
US8987206B2 (en) 2010-07-21 2015-03-24 Oleg Iliich Epshtein Method of treating attention deficit hyperactivity disorder

Also Published As

Publication number Publication date
LT5987B (lt) 2014-01-27
ES2542042A2 (es) 2015-07-29
MY158183A (en) 2016-09-15
AR082246A1 (es) 2012-11-21
GB201302653D0 (en) 2013-04-03
EA201300133A1 (ru) 2014-03-31
FI20135146L (fi) 2013-02-15
MX2013000545A (es) 2013-10-28
SE1350179A1 (sv) 2013-04-12
SG187037A1 (en) 2013-02-28
DE112011102349T5 (de) 2013-04-18
CN103124742A (zh) 2013-05-29
LT2013015A (lt) 2013-11-25
DK201370078A (en) 2013-02-14
NO20130219A1 (no) 2013-03-22
NZ606768A (en) 2015-08-28
MX361778B (es) 2018-12-17
CL2013000098A1 (es) 2015-01-16
GB2496076A (en) 2013-05-01
US20130017202A1 (en) 2013-01-17
AU2011278040B2 (en) 2016-06-02
ES2542042R1 (es) 2015-10-06
FR2962653A1 (fr) 2012-01-20
JP2013535436A (ja) 2013-09-12
GB2496076B (en) 2018-05-09
PH12013500109A1 (en) 2015-07-03
CZ2013104A3 (cs) 2013-05-29
WO2012007847A2 (en) 2012-01-19
EP2593477A2 (en) 2013-05-22
AU2011278040A1 (en) 2013-03-07
FI20135146A7 (fi) 2013-02-15
KR20140012009A (ko) 2014-01-29
EE05760B1 (et) 2016-03-15
CA2805091A1 (en) 2012-01-19
WO2012007847A3 (en) 2012-04-12
BR112013000841A2 (pt) 2016-06-07
EA029400B1 (ru) 2018-03-30
ITTO20110641A1 (it) 2012-01-16
PE20131338A1 (es) 2013-11-18
US8865163B2 (en) 2014-10-21

Similar Documents

Publication Publication Date Title
SMT201700008B (it) Composizione farmaceutica
SMT201600350B (it) Composizioni farmaceutiche
DK3246018T3 (da) Farmaceutisk sammensætning
DK2694038T3 (da) Farmaceutisk sammensætning
DK3097925T3 (da) Farmaceutisk sammensætning
BR112012031667A2 (pt) composição
BRPI1004940A2 (pt) composição farmacêutica
BR112014003052A2 (pt) composições farmacêuticas
SMT201700095B (is) Composizioni farmaceutiche per inalazione
DK2654736T3 (da) Hidtil ukendt farmaceutisk sammensætning
EE201300005A (et) Ravimkoostis
BRPI1012539A2 (pt) composições farmacêuticas
BR112012032683A2 (pt) composição
CO6930367A2 (es) Composiciones farmaceúticas
BRPI1015939A2 (pt) composição farmacêutica
GT201200303A (es) Formulaciones farmacéuticas
EP2636704A4 (en) FILM FORMING COMPOSITION
LT2865271T (lt) Pagerinta kompozicija
HUE040370T2 (hu) Gyógyszerkészítmények
EP2642979A4 (en) PHARMACEUTICAL COMPOSITION
EP2628769A4 (en) FILM FORMING COMPOSITION
BR112012032980A2 (pt) composição
EP2635269A4 (en) COMBINATION COMPOSITION
CO6801722A2 (es) Composiciones farmacéuticas
EP2769718A4 (en) MEDICAL COMPOSITION

Legal Events

Date Code Title Description
MM4A Lapsed by not paying the annual fees

Effective date: 20180715